Sirtex profit grows 30% in FY14
Sirtex Medical (ASX:SRX) grew its net profit for the financial year ending in June by 30.6% to $23.9 million, thanks to higher sales of its SIR-Spheres liver cancer treatment microspheres.
Sales revenue grew 33.7% to a record $129.4 million, with dose sales increasing to 8561 - another company record.
SIR-Spheres deliver targeted radiation therapy to liver cancers. The product is on sale in the Americas, EMEA and Asia-Pacific.
Revenue from the Americas grew 37.4% to $96 million, thanks to a 22.5% increase in dose sales. EMEA sales were up 24.6% to $27.7 million, but dose sales increased a slimmer 5.6%. APAC revenue increased 20.9% to $5.7 million and dose sales grew 12.4% to 809 units.
Sirtex CEO said the company had delivered “another solid result” during the financial year. “We believe our current growth rate is sustainable. However, a positive result from our clinical studies should see an acceleration or step change in our growth.”
The company is currently engaged in the multi-year Sirflox marketing study and expects the results from the trial to help convince more clinicians to take up SIR-Spheres as a first-line treatment for liver cancer.
The study completed recruitment in April 2013, and results are expected to be released in 2015.
Sirtex Medical (ASX:SRX) shares were trading 0.2% lower at $20.00 as of around 2 pm on Wednesday.
Personality influences the expression of our genes
An international research team has used artificial intelligence to show that our personalities...
Pig hearts kept alive outside the body for 24 hours
A major hurdle for human heart transplantation is the limited storage time of the donor heart...
Breakthrough antibiotic for mycobacterial infections
The antibiotic candidate, named COE-PNH2, has been optimised to target Mycobacterium...